CYBG Share News (CYBG)

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------J Sainsbury, up 3.8%. The supermarket chain is not talking to internal candidates to replace Chief Executive Mike Coupe who still has the support of the company's board, Reuters reported on Saturday. The news came following reports from the Daily Telegraph that the supermarket chain was preparing a succession plans and potential replacements for Coupe. John Rogers, the boss of Argos and Paul Mills-Hicks, the Sainsbury's food commercial director, were reportedly among the candidates considered. In a statement given to Reuters, Sainsbury's said: "We are not talking to internal candidates about succession planning for Mike and have been clear he has the full support of shareholders and the board."----------FTSE 100 - LOSERS----------Fresnillo, down 1.2% at 655.40 pence. The gold miner was tracking spot gold prices lower, quoted at USD1500.70 an ounce Monday, compared to USD1,509.11 late Friday. "Gold remains above USD1,500 this morning and is only a little off its highs even as the dollar has recovered and risk appetite improved. While gold bulls are clearly very reluctant to let the momentum slip, the yellow metal didn't rally too strongly during the mid-week freak out although perhaps that's a sign that risk appetite is not the biggest driver right now," said Oanda analyst Craig Erlam. Midcap peers Hochschild Mining and Centamin were down 3.2% and 3.0% respectively. ----------FTSE 250 - WINNERS----------CYBG, up 5.1%. UBS raised the challenger bank to Buy from Neutral.----------OTHER MAIN MARKET AND AIM - WINNERS----------IXICO, up 25%. The data analytics company said it anticipates annual results to be "materially" ahead of current market expectations. IXICO said it has continued to see strong growth in revenue in the second half of the year due to new and expanded contracts coming on line, deployment of newly developed algorithms and faster turnaround times in trial initiation. The company further confirmed that it anticipates the improved revenue performance to drive additional operating leverage and build on the breakeven position that it reported at the first half.Motif Bio, up 10%. The biopharmaceutical firm said the US government will fund a study on the effectiveness of the iclaprim drug against listeria monocytogenes. The National Institute of Allergy and Infectious Diseases, part of the US Department of Health & Human Services, will also be providing Motif Bio with preclinical services through JMI Laboratories. Motif said Iclaprim has previously "demonstrated consistent extracellular and intracellular activity" against listeria monocytogenes, a bacteria that can cause a listeriosis. The food-borne illness is potentially life-threatening and it infects 1,600 people in the US every year, killing 260, Motif Bio said. ----------OTHER MAIN MARKET AND AIM - LOSERS----------BATM Advanced Communications, down 1.0%. The networking solutions and medical technology provider said it swung to pretax profit in the first half of 2019, but revenue slipped on weakness in the Networking & Cyber unit. The company recorded pretax profit of USD1.2 million for the six months to the end of June, compared with USD1.3 million loss reported a year earlier. Revenue slipped to USD56.2 million from USD58.2 million. BATM Advanced explained that it has a strong backlog and is on track to deliver "significantly" higher revenue in the second half of 2019 - its seasonally stronger period - compared with the first half of 2019, along with improved margins, in line with the board's expectations. ----------